Journal
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume 12, Issue -, Pages -Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758835920915980
Keywords
antibody-drug conjugates; breast cancer; triple negative breast cancer
Categories
Ask authors/readers for more resources
Triple negative breast cancer (TNBC) is a heterogenous subtype of breast cancer often associated with an aggressive phenotype and poor prognosis. Antibody-drug conjugate (ADC), comprising of a monoclonal antibody linked to a cytotoxic payload by a linker, is gaining increasing traction as an anti-cancer therapeutic. Emerging ADC drugs such as sacituzumab govitecan (IMMU-132) and trastuzumab deruxtecan (DS-8201a) are in late stages of clinical development for patients with metastatic breast cancer, including TNBC. In this article, we review and discuss the development and clinical application of ADCs in patients with advanced TNBC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available